LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that's pioneering proton therapy systems for treating tumors ...
The Global Biotech Handbook offers opportunities in the biotech sector by detailing regulatory landscapes, clinical trial procedures, intellectual property issues, and market structures across 70 ...
PharmAla Biotech Holdings Inc. ('PharmAla” or the 'Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on ...
An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding ...
Even when promising clinical trials exist, and the FDA allows expanded access, rare disease patients like my granddaughter are often left out.
The Clinical Research Transformation: Future Outlook 2026 conference opened today, Monday, in Riyadh. Organized by King ...
The recently passed federal defense budget for 2026 includes dedicated funding for the use of bioengineered blood vessels ...
The 2026-27 Union Budget highlights ambitious science initiatives, yet critical funding gaps for basic research remain a concern.
Iowa bill would keep medical spa fines confidential, expand state oversight ...
The company, based in Norcross, GA, manufactures more than 900 DNA and RNA isolation products used in clinical research, biotechnology, genomics, and agriculture.
Cliff Greenberg discusses Baron Small Cap Fund's Q4 performance and outlook for 2026. Read the full analysis of key winners ...
The Wasatch Micro Cap Value Fund—Investor Class lagged the benchmark and finished the quarter with a return of 0.11%. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results